slides · global inventory
All filtered slides
Global slide inventory for the active corpus filters, with each row opening the slide detail view.
Corpus coverage
319,975 slides
319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.
- Total slides
- 319,975
- Described
- 319,974
- Pending
- 1
100%ready for canon
Slide type composition
dynamicclickable
Slide type
Showing 319,974 described slides — 100.0% of 319,975 rendered pages
+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs
Tile area is proportional to slide count. Click a category to open its subtype map.
all document kinds · all orientations
Slide collection
224,131-224,160 of 319,975
80
Kering | ESG Presentation Deck | 80 slidesKering | ESG Presentation Deck | 80 slides · Moelis & Company
Conference presentation Investor relations Beat · Return with Elixir1 hit
01
KeyCorp | Investor Conference Presentation Deck | 5 slidesKeyCorp | Investor Conference Presentation Deck | 5 slides · KeyCorp
Conference presentation Investor relations 1 hit
02
KeyCorp | Investor Conference Presentation Deck | 5 slidesKeyCorp | Investor Conference Presentation Deck | 5 slides · KeyCorp
Conference presentation Investor relations 1 hit
03
The slide uses a 2x2 grid of strategic pillars followed by a row of 5 key performance metrics.KeyCorp | Investor Conference Presentation Deck | 5 slides · KeyCorp
Conference presentation Investor relations Beat · Solution1 hit
04
KeyCorp | Investor Conference Presentation Deck | 5 slidesKeyCorp | Investor Conference Presentation Deck | 5 slides · KeyCorp
Conference presentation Investor relations 1 hit
05
The slide uses a table format to compare quarterly and annual guidance against prior periods.KeyCorp | Investor Conference Presentation Deck | 5 slides · KeyCorp
Conference presentation Investor relations 1 hit
01
Includes company logo and date.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · Attention1 hit
02
Kymera | Investor Presentation Deck | 46 slidesKymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · Attention1 hit
03
Kymera | Investor Presentation Deck | 46 slidesKymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · Attention1 hit
04
Kymera | Investor Presentation Deck | 46 slidesKymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · Interest1 hit
05
TPD stands for Targeted Protein Degradation. The slide uses a three-column framework to explain their competitive advantage.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · InterestLoop · Logic Chain1 hit
06
The slide uses a standard pharmaceutical pipeline table format.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · InterestLoop · Logic Chain1 hit
07
This is a stylistic section divider slide with an abstract background.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · DesireLoop · Logic Chain1 hit
08
The slide uses a biological pathway diagram to illustrate the mechanism of action for a drug candidate.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · DesireLoop · Logic Chain1 hit
09
Includes a mechanism of action diagram, a market data table, and a callout box on competitive limitations.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · DesireLoop · Logic Chain1 hit
10
Comparison of two distinct cohorts: Healthy Volunteers (SAD/MAD) vs. HS/AD Patient Cohort.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · DesireLoop · Logic Chain1 hit
11
Includes both a longitudinal line chart for IRAK4 degradation and a grouped bar chart with a supporting data table for cytokine inhibition.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · DesireLoop · Logic Chain1 hit
12
Includes PK/PD correlation, blood IRAK4 levels, skin exposure, and skin lesion IRAK4 reduction data.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · DesireLoop · Logic Chain1 hit
13
The charts show log2(fold change) for individual patients. The footnote defines the log2(fold change) values in terms of percentage decrease.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · DesireLoop · Logic Chain1 hit
14
Data compares 'All HS Patients' vs 'Moderate to Severe' subgroups across four metrics over 42 days.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · DesireLoop · Logic Chain1 hit
15
The slide includes a disclaimer that the comparison is not head-to-head and uses historical benchmarks.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · DesireLoop · Logic Chain1 hit
16
Data presented as mean +/- S.E. of mean; N=7 patients.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · DesireLoop · Logic Chain1 hit
17
The slide includes a disclaimer regarding the non-head-to-head nature of the comparison.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · DesireLoop · Logic Chain1 hit
18
The slide provides clinical safety data for the KT-474 drug candidate.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · DesireLoop · Logic Chain1 hit
19
The slide outlines the status of a partnership with Sanofi and clinical trial timelines.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · DesireLoop · Logic Chain1 hit
20
Includes clinical trial identifiers and definitions of acronyms in the footer.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · DesireLoop · Logic Chain1 hit
21
Kymera | Investor Presentation Deck | 46 slidesKymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · Action1 hit
22
Includes a table of market data and a biological pathway diagram.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · Action1 hit
23
Includes PK/PD data and efficacy metrics in multiple T-cell lymphoma models.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · Action1 hit
24
Includes box plots for gene expression and a tumor volume growth curve over time.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · Action1 hit